Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.
Annals of Oncology（2015）
摘要
XELOX or FOLFOX should be considered as standard treatment options for the adjuvant management of stage III colon cancer in all age groups and in patients with comorbidities.
更多查看译文
关键词
age groups,capecitabine,adjuvant chemotherapy,colon cancer,comorbidity,oxaliplatin
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要